Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Next-Generation Version of Recombinant Human Interferon-Beta: A Molecular Dynamic Simulation Study Publisher



Haji Abdolvahab M1, 2 ; Vafaee R3 ; Arab SS3 ; Behmanesh M2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, 1517964311, Tehran, Iran
  2. 2. Department of Genetics, Tarbiat Modares University, Tehran, Iran
  3. 3. Department of Biophysics, Tarbiat Modarres University, Tehran, Iran

Source: Informatics in Medicine Unlocked Published:2022


Abstract

The ability of recombinant human interferon beta-1b (IFNβ-1b) to elicit the production of anti-IFNβ-1b antibodies becomes a significant issue for interferon therapy in patients. Mitigating the immunogenicity issues requires understanding the stimulating factors in observed immune responses. Among multiple factors, epitopes might be the main reason for the observed immunogenicity of this drug. In this study, we investigate the ability of epitopes in IFNβ-1b to bind to the MHC class II receptors. We applied point mutations to reduce the binding affinity of the existing epitopes of IFNβ-1b to MHC class II molecules. Several bioinformatics methods were applied to compare the binding affinity of both native and mutated epitopes to the MHC class II receptors. We identified three residues, Tyrosine 3, Tyrosine 132, and Glycine 162, that if altered to Leucine, Leucine, and Glutamate, respectively, leads to a decline in the binding affinity of IFNβ-1 b's epitope to the MHC class II receptors. This suggests that we can decline the binding affinity of therapeutic IFNβ-1b in silico by introducing those point mutations. © 2022 The Authors
Experts (# of related papers)